Paula D'ambrosio

Ms. Paula D'ambrosio

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2024 in Clinics
Verified
Journal Article
Open access
DCDanilo Caribé Carneiro
Danilo Caribé Carneiro
PDPaula D'ambrosio
Paula D'ambrosio
AMAlessandro Mariani
Alessandro Mariani
JFJaqueline Schaparini Fonini
Jaqueline Schaparini Fonini
GAGabriela Ketherine Zurita Aguirre
Gabriela Ketherine Zurita Aguirre
PPPaulo Manuel Pêgo-Fernandes
Paulo Manuel Pêgo-Fernandes
Objective: : This study aims to correlate the RAPID score with the 3-month survival and surgical results of patients undergoing lung decortication with stage III pleural empyema. Methods: : This was a retrospective study with the population of patients with pleural empyema who underwent pulmonary decortication between January 2019 and June 2022. Data were collected from the institution's database, and patients were classified as low, medium, and high risk according to the RAPID score. The primary outcome was 3-month mortality. Secondary outcomes were the length of hospital stay, readmission rate, and the need for pleural re-intervention. Results: : Of the 34 patients with pleural empyema, according to the RAPID score, patients were stratified into low risk (23.5 %), medium risk (47.1 %), and high risk (29.4 %). The high-risk group had a 3-month mortality of 40 %, while the moderate-risk group had a 6.25 % and the low-risk group had no deaths within 90 days, confirming a good correlation with the RAPID score (p < 0.05). Sensitivity and specificity for the primary outcome in the high-risk score were 80.0 % and 79.3 %, respectively. The secondary outcomes did not reach statistical significance. Conclusions: : In this retrospective series, the RAPID score had a good correlation with 3-month mortality in patients undergoing lung decortication. The morbidity indicators did not reach statistical significance. The present data justifies further studies to explore the capacity of the RAPID score to be used as a selection tool for treatment modality in patients with stage III pleural empyema.

27 August 2022 in Clinics
Verified
Journal Article
Open access
PDPaula D'ambrosio
Paula D'ambrosio
PAPedro Henrique Xavier Nabuco de Araújo
Pedro Henrique Xavier Nabuco de Araújo
EJEserval Rocha Junior
Eserval Rocha Junior
MFMauro Razuk Filho
Mauro Razuk Filho
PPPaulo Manuel Pêgo-Fernandes
Paulo Manuel Pêgo-Fernandes
RTRicardo Mingarini Terra
Ricardo Mingarini Terra
Empyema is a complication of talc-pleurodesis that may lead to further surgical intervention and death. Therefore, the present study's objective was to identify the risk factors for the development of post-pleurodesis empyema after talc slurry pleurodesis in order to better select patients for this procedure and minimize its morbidity. Patients with malignant pleural effusion who underwent talc slurry pleurodesis at the present institution from January 2018 to January 2020 were retrospectively analyzed. Post-pleurodesis empyema was defined as pleural infection up to 30 days after pleurodesis. Using Cox regression analysis, significant prognostic factors for the development of empyema were examined. Of the 86 patients identified for inclusion in the study, 62 were women (72%). Their mean age was 56.3±12.6 years. The median pleural drainage time was 9 days, and 20 patients (23.3%) developed empyema. In the univariate analysis, both drainage time (p = 0.038) and the use of antibiotics prior to pleurodesis (p < 0.001) were risk factors for pleural empyema. Multivariate analysis also identified the use of antibiotics as an independent risk factor (Odds Ratio [OR] 9.81; 95% Confidence Interval [95% CI] 2.87‒33.54). Although the pulmonary expansion was not associated with empyema in the multivariate analysis, patients with less than 50% pulmonary expansion had a 4.5-times increased risk of empyema (95% CI 0.90‒22.86; p = 0.067), and patients with 50‒70% pulmonary expansion had a 3.8-times increased risk of empyema (95% CI 0.98‒15; p = 0.053) after pleurodesis. The study suggests that antibiotic therapy prior to talc slurry pleurodesis may increase the risk of developing empyema. Furthermore, pleurodesis should be considered with caution in patients with long-duration chest tube placement and incomplete lung expansion.

1 June 2025 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
BBBenoit Jacques Bibas
Benoit Jacques Bibas
MCMariana Rodrigues Cremonese
Mariana Rodrigues Cremonese
PDPaula D'ambrosio
Paula D'ambrosio
ARAna Carolina de Rezende
Ana Carolina de Rezende
SFSergio Leonardo Favareto
Sergio Leonardo Favareto
RTRicardo Mingarini Terra
Ricardo Mingarini Terra
Primary malignant tracheal tumors (PMTTs) are rare, representing less than 0.5% of all cancers. The predominant histological variants are adenoid cystic carcinoma and squamous cell carcinoma. Because of the trachea’s functional reserve, symptoms often appear only after significant airway obstruction, delaying diagnosis. Surgical resection with primary reconstruction is the preferred treatment when feasible. Resections longer than 40 mm are associated with higher anastomotic risk, and the decision between complete (R0) or microscopically incomplete (R1) resections must consider patient-specific anatomy and the potential for adjuvant radiotherapy. In selected cases, R1 resection followed by radiation achieves outcomes comparable to R0 resection. Endoscopic interventions can restore airway patency and are indicated in patients who are unresectable, inoperable, or require bridging to definitive treatment. However, they are palliative and not curative. Imaging and bronchoscopic evaluation are essential for assessing resectability and planning the surgical approach. Management of PMTT requires a multidisciplinary strategy that integrates surgical technique, endoscopic interventions, and adjuvant therapies. Prognosis is influenced by tumor histology, resection margins, and patient-related factors. Given the rarity of PMTT, current evidence is limited, and most clinical decisions rely on retrospective data and surgical experience. This review aims to synthesize existing knowledge and highlight ongoing gaps in the literature to support more informed clinical practice and future research directions.

18 June 2022 in Clinics
Verified
Journal Article
Open access
LLLeticia Leone Lauricella
Leticia Leone Lauricella
PDPaula D'ambrosio
Paula D'ambrosio
PCPriscila Berenice da Costa
Priscila Berenice da Costa
MAMarcia Cristina Augusto
Marcia Cristina Augusto
PPPaulo Manuel Pêgo-Fernandes
Paulo Manuel Pêgo-Fernandes
RTRicardo Mingarini Terra
Ricardo Mingarini Terra
The use of Indwelling Pleural Catheter (IPC) in the care of patients with Malignant Pleural Effusion (MPE) is well established, however studies involving public health systems of low and middle-income countries are still lacking. This study aimed to determine the effect of IPC on the respiratory symptoms and Quality of Life (QoL) of patients with MPE in the setting of a Brazilian public health system. From August 2015 to November 2019, patients with MPE underwent IPC placement and were prospectively followed. QoL and respiratory symptoms were assessed by the EORTC questionnaires (QLQ-30; LC13) and Visual Analogue Scale (VAS), respectively, at pre-treatment, 30 , and 60 days after IPC placement. 56 patients were enrolled with 57 catheters inserted. The mean age was 63 (23‒88) years, of which 17 (30%) were men and 39 (70%) were women. Breast 24 (42%) and lung 21 (37%) were the main primary neoplasms. Cellulitis was the most common complication and all patients recovered with appropriate antimicrobial therapy. QoL did not change significantly over time, however, the VAS showed a significant improvement in dyspnea (+1.2: -0.5; p = 0.001). IPC relieves respiratory symptoms without compromising the QoL, with a low complication rate. It represents a suitable option for patients with MPE and short LE in an emerging country.

1 August 2023 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
AMAlessandro Wasum Mariani
Alessandro Wasum Mariani
PDPaula D'ambrosio
Paula D'ambrosio
EJEserval Rocha Junior
Eserval Rocha Junior
ANAntero Gomes Neto
Antero Gomes Neto
SFSérgio Tadeu Lima Fortunato
Sérgio Tadeu Lima Fortunato
PPPaulo Manuel Pêgo-Fernandes
Paulo Manuel Pêgo-Fernandes
Background: Chronic lung infections represent a diversity of clinical entities that combined respond to significant public health, particularly in developing countries. However, there is no data regarding the practice patterns, surgeons’ preferences, and technological usage, especially among Brazilian surgeons, in the setting of the surgical treatment of chronic lung infections. We, therefore, surveyed Brazilian thoracic surgeons from the Brazilian Society of Thoracic Surgery (SBCT) about practice patterns and trends in surgical treatment for chronic lung infections. Methods: A cross-sectional anonymous survey of all thoracic surgeons from the Brazilian Society was conducted in 2019. As the study was purely descriptive no further statistical evaluation was performed. Results: The responsive rate was 34% (259/766) from 23 of the 26 states in Brazil. A total of 141 (54.4%) participants reported their institution as a surgical reference for chronic infection lung disease, only 13.1% of surgeons have a high-volume service (more than 11 cases operated annually). The majority (76.2%) of respondents performed 1–5 surgical resection to treat tuberculosis (TB) sequelae, but only 62 (30.1%) had performed more than one resection to treat active TB. Chronic lung infection (76%) and hemoptysis (66%) were the most common symptoms as surgical indications. A proportion of 42.2% of the respondents do not have and/or perform routine drug sensitivity tests. In addition, 19.3% of respondents were not familiar with the recommendations of surgery in the treatment of pulmonary TB. Video-assisted thoracoscopic surgery (VATS) is available for 80% of respondents, while robotic surgery is for only 10%. Most (86%) surgeons have access to surgical staplers. Among the structural resources, respiratory isolation beds in the intensive care unit (ICU) (80%) and ward (79%) are frequently available resources. However, less than 12% of surgeons have in their institution a specific operating room for sputum-positive patients. Conclusions: Lung resection for chronic infectious disease is an essential area of activity for thoracic surgeons in Brazil, which occurs mainly in the public sphere, with no concentration of cases per surgeon or institution. The lack of adequate resources in many centers justifies the creation of reference centers for improving care for these patients.

1 January 2026 in mHealth
Verified
Journal Article
Open access
PDPaula D'ambrosio
Paula D'ambrosio
FPFelipe S. Passos
Felipe S. Passos
RORachid Eduardo Noleto da Nobrega Oliveira
Rachid Eduardo Noleto da Nobrega Oliveira
VAVanessa Alvarenga-Bezerra
Vanessa Alvarenga-Bezerra
PHPaula Hirayama
Paula Hirayama
RMRenato Moretti-Marques
Renato Moretti-Marques
Enhanced recovery after surgery (ERAS) programs are designed to reduce postoperative complications and accelerate recovery. Despite their proven benefits, maintaining patient adherence to these protocols remains a significant challenge. Mobile health (mHealth) applications have been introduced as potential tools to support adherence and improve perioperative outcomes; however, their effectiveness within ERAS pathways has not been clearly established. This review aims to evaluate the impact of mobile applications on protocol compliance, recovery, and clinical outcomes among surgical patients enrolled in ERAS programs. PubMed, EMBASE, and the Cochrane Library were systematically searched through February 2025 to identify studies comparing ERAS care with and without mobile application support. Due to heterogeneity in study design, outcomes, and app functionalities, a meta-analysis was not performed. The primary outcome was adherence to ERAS protocols. Secondary outcomes included quality of recovery, patient and clinician satisfaction, postoperative complication rates, hospital length of stay (LOS), and readmissions. Eight studies encompassing 1,623 patients were included. Mobile app use was associated with improved adherence to ERAS components, particularly early mobilization and oral intake. Some studies reported higher Quality of Recovery-15 (QoR-15) scores and greater patient satisfaction, although these differences were not always statistically significant. The clinician reported reductions in unnecessary visits and improved communication. No study reported an increased rate of complications. One study found that non-adherent patients had a significantly higher risk of 30-day readmission; another reported reduced infection rates and better pain control. The risk of bias was moderate in most studies. mHealth applications integrated into ERAS protocols may improve adherence, recovery quality, and patient engagement without increasing adverse outcomes. However, the overall quality of evidence remains limited due to heterogeneity and a predominance of non-randomized studies.